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Objectives: Bladder transitional cell carcinoma (TCC) is one of the most common solid malignancies in China. This
study examined the antitumor effect and underlying mechanism of action of sunitinib malate in human bladder
TCC in vitro.
Methods: Bladder TCC cell lines 5637 and BIU87 were maintained in 1640 medium and T24 cell lines in DMEM/F12
medium. All 3 cell lines were then exposed to graded concentrations (0.625-20 μmol/L) of sunitinib malate, sorafenib
and cisplatin for 24–96 hours to determine the sensitivities to each drug. Cell viability was measured by the MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium] assay, and apoptosis was analyzed by flow cytometry. Cell
apoptotic morphology was observed by a fluorescence microscope after DAPI (4′,6-diamidino-2-phenylindole)
staining. Protein concentrations were measured by western blot.
Results: Sunitinib malate showed a concentration-dependent inhibitory effect on the 5637, T24 and BIU87 cell
lines with IC50’s of 1.74 μmol/L, 4.22 μmol/L, and 3.65 μmol/L, respectively. Cisplatin also exhibited good antitumor
activity, but whereas sorafenib suppressed proliferation of the cells at concentrations of 10 μmol/L or higher, there was
practically no response at lower concentrations. Sunitinib malate treatment resulted in an accumulation of cells in the
sub-G1 phase, especially with the T24 and BIU87 cell lines, which induced apoptosis of the cells.
Conclusions: Sunitinib malate exerted marked inhibitory activity against bladder cancer cells. The cell growth inhibitory
effect of the drug was related to induction of apoptosis. These results suggest that clinical application of sunitinib-based
therapy for advanced bladder cancer is possible.
Keywords: Sunitinib, Sorafenib, Cisplatin, Bladder cancer, ProliferationIntroduction
Bladder transitional cell carcinoma (TCC) is one of the
most common solid malignancies in China. Currently,
radical cystectomy remains the standard therapy for in-
vasive TCC. However, the disease recurs in up to 50% of
patients and is potentially lethal despite surgery. Although
bladder TCC is relatively sensitive to GC (gemcitabine,
cisplatin) and MVAC (methotrexate, vinblastine, doxo-
rubicin, cisplatin), the response rate with these regimens is
no more than 50% and subsequent progression is relatively
common. Due to the poor prognosis of advanced bladder
carcinoma and the insufficient efficacy of the above
therapies, more effective treatments for metastatic and* Correspondence: ljjxmc@163.com
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unless otherwise stated.advanced bladder TCC need to be found. Thus, the in-
vestigation of novel genetic and pharmacologic agents,
including anti-angiogenic agents that can target pathway-
specific molecules, has become increasingly important.
As several receptor tyrosine kinases (RTKs), such as
the vascular endothelial growth factor (VEGF) receptors,
appear to be involved in the development of bladder
TCC, RTKs may be attractive targets for therapeutic ma-
nipulation. Sunitinib malate is a multi-RTK inhibitor that
acts on vascular endothelial growth factor (VEGF) receptors
1, 2, and 3, platelet-derived growth factor (PDGF) receptor,
stem cell factor receptor (KIT), and FMS-like tyrosine
kinase-3 receptor (FLT3). Its antitumor activity has been
demonstrated in other cancers, such as renal cell car-
cinoma (RCC), gastrointestinal stromal tumor (GIST),
non-small-cell lung cancer, and colorectal cancer [1-5].
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malate in human bladder TCC in vitro.
Methods
Cell culture
Human bladder cancer cell lines 5637, T24 and BIU87
were obtained from the Cell Culture Center of the Institute
of Basic Medical Science, Chinese Academy of Medical
Sciences, and the Cell Culture Center of the Cancer
Institute and Hospital, Chinese Academy of Medical
Sciences. The 5637 and BIU87 cell lines were maintained
in 1640 medium (Gibco, Grand Island, NY, USA) with
10% heat-inactivated newborn calf serum at 37°C in 5%
CO2, and the T24 cell lines were maintained in DMEM/
F12 medium (Gibco, Grand Island, NY, USA) with 10%
heat-inactivated newborn calf serum at 37°C in 5% CO2.
Cell viability measurement by MTT assay
Cell viability was measured by the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In
brief, cells were seeded into 96-well plates at a density
of 2 × 103/well. 24 hours later, triplicate wells were treated
with media and the test agents (at concentrations of
0.625-20 μmol/L). After incubation for 96 hours at 37°C in
5% CO2, the drug-containing medium was removed and
replaced by 100 μL fresh medium with 0.5 mg/mL MTT
solution. After incubation for 4 hours, the medium with
MTT was removed and 150 μL DMSO was added to each
well. The plates were then gently agitated until the color
reaction was uniform, and the OD570 (optical density at a
wavelength of 570 nm) was determined using a microplate
reader (Wellscan MK3, Labsystems Dragon). Microsoft®
Excel 2003 was used for data analysis. Media-only treated
cells served as the indicator of 100% cell viability. The 50%
inhibitory concentration (IC50) was defined as the concen-
tration that reduced the absorbance of the untreated wells
by 50% of that of the vehicle in the MTTassay.
Apoptosis analysis by flow cytometry (FCM) by PI staining
assay and Annexin V-FITC/PI staining assay
For PI staining assay, 5637, T24 and BIU87 cells treated
with or without the test agents at various concentrations
for 48 hours were collected by trypsinization and washed
twice with phosphate-buffered saline (PBS), then fixed in
ice-cold 70% (v/v) ethanol at −20°C for 24 hours. After
centrifugation, the cell pellets were resuspended in 1 mL of
propidium iodide (PI) solution (50 mg/mL PI, 50 mg/mL
RNase A, 0.03% Triton X-100, and 0.01% sodium citrate
in PBS) and incubated for 30 minutes at 37°C. DNA
histograms were obtained by fluorescence-activated cell
sorting analysis (FACS). In addition, Annexin V-FITC/PI
staining assay was introduced for quantitative determin-
ation of apoptotic percentage in T24 cells. After 48 hours
treatment, T24 cells were washed with PBS, stained withfluorescein isothiocyanate conjugated Annexin V and PI,
according to the manufacturer’s protocol (The ApoTarget™
Annexin-V FITC Apoptosis Kit, Invitrogen, U.S.A.), and
analyzed by flow cytometry.
DAPI (4′,6-diamidino-2-phenylindole) staining
After incubation with or without sunitinib malate for
24 hours, T24 cells were stained with DAPI (10 μg/mL
in PBS) for 30 minutes, followed by fixation with 4% PFA
(paraformaldehyde) for 15 minutes in the dark. Cell
apoptotic morphology was observed by a fluorescence
microscope (Olympus BX51, Japan) after washing with PBS.
Western blot analysis
Total cellular protein was extracted using a lysis buffer
[1% Triton X-100 (pH 7.2), 100 μg/ml phenylmethylsul-
fonyl fluoride, 10 μg/ml leupeptin, 1 μg/mL pepstatin A,
2 μg/mL aprotinin, 20 mM p-nitrophenyl phosphate,
0.5 mM sodium orthovanadate, and 1 mM 4-(2-ami-
noethyl) benzenesulfonylfluoride hydrochloride]. The
protein concentration was measured by the Bio-Rad pro-
tein assay. An equal amount of protein was separated
using 10% and 12% SDS-PAGE and transferred to
nitrocellulose membranes (Amersham, Bucks, UK). The
membranes were blocked with 5% skimmed milk in
PBS and incubated overnight with primary antibodies,
followed by horseradish-peroxidase-conjugated anti-
bodies at room temperature. β-Actin was used as an in-
ternal positive control. The primary antibodies included
Fas, FasL, PARP [poly (ADP-ribose) polymerase], and β-
actin (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Signals were visualized using an enhanced
chemiluminescence system (Amersham).
Wound healing assay
T24 cells were seeded at a density of 105 in 24 well plates
and cultured for 24 hours. Monolayers were wounded using
the tip of a pipette, washed by PBS, and further incubated
in DMEM/F12 medium with 1% FBS in the presence or
absence of sunitinib malate at different concentrations
for 24 hours. Images were acquired via a phase-contrast
microscope and the wound width was measured at vari-
ous time points.
Results
Antitumor effect of sunitinib malate versus that of
sorafenib and cisplatin
To explore the antiproliferative activity of sunitinib malate
on bladder cancer cells, small panels of the 5637, T24 and
BIU87 cell lines were initially used in the MTT assay.
Since cisplatin is widely used in clinical therapy of bladder
cancer, we used it as positive control medicine. In
addition, sorafenib, an already launched RTKs inhibitor,
was selected as control medicine with similar mechanism
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a concentration-dependent inhibitory effect on the 3
cell lines with 96 h IC50’s of 1.74 μmol/L, 4.22 μmol/L,
and 3.65 μmol/L, respectively. All 3 cell lines were also
exposed to graded concentrations (0.625-20 μmol/L) of
sorafenib or cisplatin for 96 hours to determine sensitivities
to these drugs (Table 1). At a concentration 10 μmol/L or
higher, sorafenib suppressed proliferation of the cancer
cells, but at lower concentrations there was practically no
response. However, cisplatin also exhibited good antitumor
activity (Figure 1).Induction of apoptosis by sunitinib malate
To investigate whether apoptosis is involved in the growth
inhibitory effect of sunitinib malate, we determined its ef-
fect firstly by flow cytometry following PI staining and
Annexin V-FITC/PI staining assay. As shown in Figure 2A,
sunitinib malate treatment resulted in an accumulation
of cells in the sub-G1 phase, especially with the T24 and
BIU87 cell lines. After that, the most sensitive cell line,
T24, was chosen to perform the Annexin V-FITC/PI stain-
ing assay for quantitative determination of apoptotic cells.
Annexin V is usually used to detect the translocation of
phosphatidylserine during early stages of apoptosis due
to its high affinity for phosphatidylserine. Early apoptotic
cells are positive for Annexin V-FITC only while late
apoptotic cells are positive for both dyes. Viable cells
should be stained negatively. As shown in Figure 2B,
sunitinib malate treatment induced a markedly increase
in the percentage of apoptotic cells in a dose-depended
manner.Figure 1 Antitumor effects of sunitinib malate, sorafenib and cisplatin
graded concentrations of 0.625-20 μmol/L of the 3 drugs for 24–96 hTo further investigate its apoptotic effect, morphologic
analysis via DAPI staining and fluorescence microscopy
was employed for the T24 cell line. After 48 hours of ex-
posure to sunitinib malate (0.3125-10 μmol/L), T24 cells
showed unusual changes in their nuclei. As shown in
Figure 3, at concentrations of 1.25 μmol/L or higher, small
holes appeared in the nuclei of T24 cells and the holes
were bigger with higher concentrations. In comparison,
the nuclei of untreated T24 cells and those exposed to
lower concentrations of sunitinib malate (0.3125 and
0.625 μmol/L) exhibited normal morphology.
It is well known that cellular apoptosis is associated
with alterations in two main signaling pathways termed
the extrinsic and intrinsic pathways. Yoon et al. [6] have
shown that the intrinsic pathway is involved in the cell
growth inhibitory effect of sunitinib malate, and protein
expression in the extrinsic pathway, which is also known
as the death receptor pathway, was also detected. Death
receptors are members of the tumor necrosis factor (TNF)
receptor gene superfamily that consists of more than
20 proteins, the best known of which is Fas (CD95),
which has FasL (CD95L) as its corresponding ligand.
As shown in Figure 4, the expression of FasL in T24
cells treated with sunitinib malate (1.25-10 μmol/L for
48 h) exhibited a significant concentration-dependent
increase, but there was practically no change in the ex-
pression of Fas.
Cleavage of PARP is also an established and reliable
apoptosis indicator downstream of caspase activation. As
shown in Figure 4, T24 cells exhibited a concentration-
dependent increase of PARP cleavage when exposed to
sunitinib malate.on the 3 human bladder cancer cell lines following exposure to
ours (MTT assay).
Table 1 Antiproliferative effect of drugs against bladder
cancer cell lines
Drug IC50 values (96 h) [μmol/L]
5637 T24 BIU87
Sunitinib 1.74 4.22 3.65
Sorafenib 9.09 15.44 15.08
Cisplatin 6.69 2.87 0.22
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As it is well established that successful wound healing
involves a number of processes, including cell migration
and polarity, we performed a wound healing analysis to
examine whether sunitinib malate affects these processes.
As shown in Figure 5, sunitinib malate suppressed theFigure 2 Apoptosis analysis by flow cytometry. A, flow cytometric anal
following Sunitinib treatment. Cells were treated with Sunitinib for 48 h for in
cells provided an estimate of apoptotic cells. B, Apoptosis detected by Annex
stained with Annexin V and PI before subjected to FACS for analysis.wound healing process significantly in a concentration-
dependent manner.
Discussion
Sunitinib malate is a novel anti-angiogenic agent that has
recently been demonstrated to improve progression-free
survival in patients with metastatic renal cell carcinoma
[7]. It is a small-molecule multi-RTK inhibitor that dir-
ectly inhibits VEGFR, PDGFR, KIT, and FLT3. In patients
with bladder cancer, the expression level of VEGF mRNA
and the serum level of VEGF have been found to be asso-
ciated with the cancer stage, grade, vascular invasiveness,
and metastases [8-10]. It has also been shown that VEGF
is abnormally over-expressed in TCC and promotes
cancer malignancy [11]. These findings suggest a possible
antitumor and anti-angiogenic effect of sunitinib malate in
advanced bladder TCC. Thus far, however, there have beenysis of propidium iodide stained DNA of three bladder cancer cell lines
dicated concentration. Increased sub-G1 fraction the Sunitinib -treated
in V-FITC/PI binding assay. Cells treated with Sunitinib for 48 h were
Figure 3 Morphologic changes in T24 cells treated with sunitinib (A: 0 μmol/L; B: 0.3125 μmol/L; C: 0.625 μmol/L; D: 1.25 μmol/L; E:
2.5 μmol/L; F: 5 μmol/L; G: 10 μmol/L). After exposure to different concentrations of sunitinib malate for 24 hours, the cells were stained with
DAPI and examined using florescence microscopy (magnification 200 ×).
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action of sunitinib malate in bladder cancer [12].
In the present study, we firstly used MTT assay to ex-
plore the antitumor effect of sunitinib malate on 3 human
bladder cancer cell lines. Although two of them, T24
and BIU87, originated from transitional urinary bladder
carcinoma, and 5637 originated from GradeIIurinary
bladder carcinoma, both of them showed high sensitivity
to sunitinib malate therapy. In addition, we also compared
sunitinib malate with another small-molecule multi-RTK
inhibitor sorafenib and a conventional chemotherapeutic
agent cisplatin. We found that both sunitinib malate
and cisplatin exhibited a significant inhibitory effect
against these cancer cells, but the cells were less sensi-
tive to sorafenib. This finding points to the possibility
of clinical application of sunitinib for advanced bladder
cancer therapy.Figure 4 Western blot analysis of protein expression of T24 cells tre
(1.25 μmol/L, 2.5 μmol/L, 5 μmol/L and 10 μmol/L) for 48 hours, and wes
β-actin is shown. β-Actin levels are shown as an internal control.Although sunitinib malate is a widely used drug with
multiple targets, we did not examine its effect on targets
such as VEGFR, PDGFR and KIT etc., in the TCC cell
lines utilized in our study. What we were interested in is
whether sunitinib malate can induce apoptosis and other
characteristic changes in the cells. Flow cytometry ana-
lysis showed that sunitinib malate treatment resulted in
accumulation of cells in the sub-G1 phase, especially with
T24 and BIU87 cell lines, which could partially explain its
growth inhibitory effect on these cells. Moreover, the
morphologic analysis following DAPI staining showed
an unusual change in the nuclei of T24 cells, a single hole,
after exposure to sunitinib malate, which was probably an
early apoptosis phenomenon.
Yoon et al. [6] have previously shown that sunitinib
malate treatment significantly increased expression of the
pro-apoptotic proteins Bax and Bad, indicating that theated with sunitinib malate. T24 cells were exposed to sunitinib
tern blot analysis with antibodies specific for Fas, FasL, PARP and
Figure 5 Effect of Sunitinib on wound healing. Confluent monolayers of T24 cells were mechanically wounded with the tip of a pipette. After
24 hours incubation with sunitinib with different concentration, images were taken under a phase-contrast microscope.
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inhibitory effect of the drug. The concentration-
dependent augmentation of FasL by sunitinib malate
noted in our study suggests a possible involvement of
the extrinsic apoptosis pathway in the antitumor ac-
tion of the drug against TCC.
As discussed above, the cleavage of PARP is an estab-
lished and reliable apoptosis indicator downstream of cas-
pase activation, and is a fairly early event in apoptosis.
PARP is a nuclear DNA-binding protein that detects DNA
strand breaks and functions in base excision repair.
However, once PARP is cleaved, it no longer supports the
enzymatic DNA repair function, and there is increasing
evidence that cleaved PARP may inhibit access to DNA by
other repair enzymes. Several studies have indicated that
PARP cleavage is detectable earlier than other events
associated with apoptosis such as DNA fragmentation.
Our study found that T24 cells exhibited a concentration-
dependent increase in PARP cleavage when exposed to
sunitinib malate which might partially explain the mor-
phologic findings following DAPI staining.
To gain further insight into the effects of sunitinib mal-
ate on other characteristics of TCC, we examined its effect
on cell migration and polarity via a wound healing assay
and found that it suppressed the wound healing process
significantly in a concentration-dependent manner. This
finding further suggests its possible usage in the treatment
of TCC.
In conclusion, we found that sunitinib malate exerted
marked inhibitory activity against bladder cancer cells,
and the cell growth inhibitory effect was related to induc-
tion of apoptosis. We also showed that sunitinib malate
can suppress the motility of T24 bladder cancer cells.
These findings point to the possible clinical application
of sunitinib-based therapy for advanced bladder cancer.
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